A compliance headache?
In recent years, a number of transfer pricing-related disputes between multinational corporations and tax authorities have made the headlines. Of particular note is the $3.4bn settlement between GlaxoSmithKline and the Internal Revenue Service in the United States and AstraZeneca’s approximately £500m settlement in the United Kingdom. These eye catching numbers are just the tip of…